Clinical trials: Post-Transplant
Aortic Aneurysm, Abdominal
Post-Approval Trial of the Talent™ Abdominal Stent Graft to Treat Aortic Aneurysms
The purpose of this study is to examine, through the endpoints established in this protocol, the long-term safety and effectiveness of the Talent Abdominal Stent Graft System, in a post-approval environment.
- Trial name
- VITALITY (NCT00816062)
- Testing
- Talent Abdominal Stent Graft
- Where
- 18 sites in United States
- Volunteers
- 94 people
- Sponsor
- Medtronic Cardiovascular
Leukemia/Lymphoma, Cutaneous T Cell Lymphoma
Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With Mogamulizumab
This is a non-interventional cohort study evaluating non-relapse mortality and toxicities in patients with CTCL or ATLL treated with mogamulizumab pre- or post- alloHCT for patients transplanted beginning January 1, 2012 until…
- Conditions
- Leukemia/Lymphoma, Cutaneous T Cell Lymphoma, ATLL
- Trial name
- NCT04014374
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Kyowa Kirin, Inc.
Recurrent Hepatocellular Carcinoma
A Study of TCR-Redirected T Cell Infusion in Subject With Recurrent HBV-related HCC Post Liver Transplantation
Hepatocellular carcinoma (HCC) recurrence rate is high among liver transplant patients, while treatment measures are limited. This study plans to recruit 10 patients with Hepatitis B virus (HBV) related HCC who underwent liver…
- Trial name
- NCT02719782
- Testing
- Biological: TCR-T
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Lion TCR Pte. Ltd.
Graft vs Host Disease
Activity, Safety and Pharmacokinetics in Pediatric Subjects With Moderate and Severe Chronic Graft vs. Host Disease After Allogeneic Stem Cell Transplant
This open-label, single-arm, Phase II multi-center study enrolled 46 participants and investigated the activity, pharmacokinetics and safety of ruxolitinib added to the subject's immunosuppressive regimen among infants, children…
- Trial name
- REACH 5 (NCT03774082)
- Testing
- INC424
- Where
- 21 sites in Brazil, Canada and 12 more
- Volunteers
- 46 people
- Sponsor
- Novartis Pharmaceuticals
Liver Transplantation
A Multicenter Study in Liver Transplant Patients Converted From Prograf® to Advagraf® During the First Post-transplantation Year
A study in which two groups of patients will be analysed; patients converted from Prograf to Advagraf within the first 3 months after transplantation and patients converted from Prograf to Advagraf between 3 months and 1 year…
- Trial name
- COBALT (NCT02143479)
- Testing
- Tacrolimus
- Where
- 18 sites in France
- Volunteers
- 398 people
- Sponsor
- Astellas Pharma S.A.S.
Liver Transplant, Hepatitis C
Liver Fibrosis in Patients Transplanted for Hepatitis C Receiving Either Cyclosporine Microemulsion or Tacrolimus
Following a transplant for hepatitis C cirrhosis, the infection comes back in 70-90% of cases and over time causes fibrosis and eventually cirrhosis of the new liver.
- Trial name
- NCT00260208
- Testing
- Cyclosporine A, Tacrolimus
- Where
- 2 sites in United States, Switzerland
- Volunteers
- 361 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Graft Versus Host Disease
Safety and Efficacy of Oral Belumosudil in Black or African American, American Indian or Alaska Native, and Native Hawaiian or Other Pacific Islander Male and Female Participants Aged 12 Years and Above With Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy
The purpose of this study is to measure safety and efficacy of oral belumosudil in Black or African American, American Indian or Alaska Native, and Native Hawaiian or Other Pacific Islander male and female participants with cGVHD…
- Trial name
- NCT05567406
- Testing
- Belumosudil
- Sponsor
- Kadmon, a Sanofi Company
Anemia
A Study of Subcutaneous Mircera, Versus no Erythropoiesis-Stimulating Agent (ESA) Therapy, in the Treatment of Anemia in Patients With Chronic Kidney Disease After Kidney Transplant
This 2 arm study will assess the efficacy, safety and tolerability of subcutaneous Mircera, versus no ESA therapy, in chronic kidney disease patients with anemia after kidney transplant, not currently treated with ESA.
- Trial name
- NCT00576602
- Testing
- methoxy polyethylene glycol-epoetin beta [Mircera], Supportive treatment
- Where
- 20 sites in Belgium, France and 4 more
- Volunteers
- 1 people
- Sponsor
- Hoffmann-La Roche
Liver Transplant
Efficacy and Safety of Once-Daily Tacrolimus in Liver Transplant Recipients (SOUL)
The purpose of this study is to evaluate the efficacy and safety of conversion to TacroBell slow-release cap.(Once-daily Tacrolimus) in patients undergoing maintenance therapy with Twice-Daily Tacrolimus after liver…
- Trial name
- NCT04069065
- Testing
- Conversion to Once-daily Tacrolimus
- Where
- South Korea
- Volunteers
- 146 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Acute Lymphoblastic Leukemia, Leukemia, Acute Myeloid (AML), Child
Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant
This study will evaluate pediatric patients with malignant or non-malignant blood cell disorders who are having a blood stem cell transplant depleted of T cell receptor (TCR) alfa and beta cells that comes from a partially…
- Conditions
- Acute Lymphoblastic Leukemia, Leukemia, Acute Myeloid (AML), Child, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes
- Trial name
- NCT03301168
- Testing
- BPX-501 T cells, Rimiducid
- Where
- 10 sites in United States
- Volunteers
- 120 people
- Sponsor
- Bellicum Pharmaceuticals
Abdominal Aortic Aneurysm, AAA
E-tegra Stent Graft System in the Treatment of Infra-renal Abdominal Aortic Aneurysms
The purpose of this study is to evaluate clinical and technical success as well as safety and feasibility of the E-tegra Stent Graft System used in endovascular treatment of infrarenal aortic aneurysm.
- Trial name
- SECURE (NCT02485496)
- Testing
- Endovascular abdominal repair
- Where
- 10 sites in France, Germany and 3 more
- Volunteers
- 38 people
- Sponsor
- JOTEC GmbH
Cytopenia
Clinical Trial In The Treatment Of Allogeneic Post-Transplant Cytopenias With Sequential Infusion Of Allogeneic Mesenchymal Cells Expanded In Vitro
The purpose of this study is to evaluate the safety and efficacy of the sequential infusion of allogeneic mesenchymal stem cells (MSC), expanded "in vitro" with platelet lysate without addition of animal products in the treatment…
- Trial name
- NCT02104440
- Testing
- Sequential infusion of allogeneic mesenchymal stem cells expanded "in vitro"
- Where
- Spain
- Volunteers
- 15 people
- Sponsor
- Red de Terapia Celular
Cytomegalovirus (CMV)
A Study of Maribavir in Adults and Children With Post-transplant Cytomegalovirus (CMV) Infection in Argentina
The main aim of this study is to learn about the safety of Maribavir in adults and children with post-transplant CMV infection in routine clinical practice in Argentina.
- Trial name
- NCT06213974
- Testing
- No Intervention
- Where
- Argentina
- Volunteers
- 28 people
- Sponsor
- Takeda
Acute Graft Versus Host Disease
A Study of AbGn-168H in Patients With Steroid Refractory Acute Graft-vs-Host Disease After Donor Stem Cell Transplant
This study is to establish the safety, determine if there is an improvement in steroid refractory acute graft-vs-host disease (aGvHD) compared to historical cohorts, and determine the changes of aGvHD-associated T-cell clones in…
- Trial name
- NCT02436460
- Testing
- AbGn-168H
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- AbGenomics B.V Taiwan Branch
Thoracoabdominal Aortic Aneurysm
A PMCF Study in Patients With Thoracoabdominal Aortic Aneurysms Treated With E-nside TAAA Multibranch Stent Graft System (INNER-B-APAC)
The INNER-B-APAC post-market clinical follow-up study is undertaken to demonstrate the safety and clinical performance of the E-nside TAAA Multibranch Stent Graft System used in endovascular treatment of patients with…
- Trial name
- NCT05954793
- Where
- 8 sites in Australia, New Zealand and 1 more
- Volunteers
- 16 people
- Sponsor
- JOTEC GmbH
Liver Transplantation
A Clinical Study to Evaluate the Efficacy and Safety of LIV-GAMMA SN Inj. in ABO-Incompatible Liver Transplantation
The purpose of this study is to evaluate the efficacy and safety of LIV-GAMMA SN Inj. administered for consecutive 3 days in adult subjects to prevent biliary complications after ABO incompatible adult to adult living donor liver…
- Trial name
- NCT05666453
- Testing
- LIV-GAMMA SN Inj., No intervention
- Where
- 5 sites in South Korea
- Volunteers
- 59 people
- Sponsor
- SK Plasma Co., Ltd.
Thoracic Aortic Dissection
Post-market Clinical Trial of the Dominus® Stent-Graft
Real-world clinical trial evidence post-market, evaluating the safety and efficacy of the Dominus® StentGraft Endoprosthesis in treating thoracic aortic diseases, following the Instructions for Use
- Trial name
- DominusPMCF (NCT06270537)
- Testing
- Stent-Graft Dominus® Endoprosthesis
- Where
- 3 sites in Brazil
- Volunteers
- 100 people
- Sponsor
- Braile Biomedica Ind. Com. e Repr. Ltda.
Adenovirus
The AdAPT Trial; Adenovirus After Allogeneic Pediatric Transplantation
This study was designed to assess the safety, overall tolerability, and antiviral activity of "short course" brincidofovir (BCV) therapy, as compared with current standard of care (SoC), for the treatment of adenovirus (AdV)…
- Trial name
- AdAPT (NCT03339401)
- Testing
- Standard of Care, Brincidofovir
- Where
- 36 sites in United States, France and 7 more
- Volunteers
- 29 people
- Sponsor
- Jazz Pharmaceuticals
Aortic Aneurysm, Abdominal
Post-Approval Study of the Ovation™/Ovation Prime™ Abdominal Stent Graft System
The Post-Approval Study (PAS) will evaluate the "real world" data on the Ovation™/Ovation Prime™ Abdominal Stent Graft System along with the long-term data collected from the IDE cohort to monitor the long-term safety and…
- Trial name
- NCT01980901
- Testing
- Ovation™/Ovation Prime™ Abdominal Stent Graft System
- Where
- United States
- Volunteers
- 320 people
- Sponsor
- TriVascular, Inc.
Penetrating Ulcer of Aorta, Aneurysm Aortic
Evaluation of the Valiant Captivia Physician Fenestrated Stent Graft System in Aortic Arch and Descending Thoracic Aorta Pathologies
The study objectives are to assess safety and effectiveness, measured acutely and at the 30-day visit after implantation of the Valiant Captivia physician fenestrated Stent Graft.
- Conditions
- Penetrating Ulcer of Aorta, Aneurysm Aortic, Type B Aortic Dissection, Residual Dissection After Type A Repair
- Trial name
- EVERGREEN (NCT05479305)
- Testing
- The Valiant Captivia Stent Graft
- Where
- 4 sites in France
- Volunteers
- 30 people
- Sponsor
- Ceric Sàrl